Uncovering the evolutionary history of IBD-associated colorectal cancer

July 11, 2018, Queen Mary, University of London

A team of researchers from Queen Mary University of London have reported the genetic events involved in the early development of bowel cancer in patients with inflammatory bowel disease (IBD).

Such knowledge may be able to be exploited to design simple diagnostic tests to stratify patients with IBD at high risk of developing cancer.

IBD more than doubles an individual's lifetime risk of developing , and the risk increases significantly if they have suffered with IBD for a sustained period of time. With this in mind, the study published in Gut performed in collaboration with researchers from St Mark's Hospital and the University of Oxford set out to understand the genetics of how colorectal cancer develops in people with IBD.

Lead researcher Professor Trevor Graham from Barts Cancer Institute at Queen Mary said: "Predicting who with IBD is going to go on to develop cancer is a big unmet need. If we could do it accurately, it would allow us to target care to those who need it most, and spare low-risk individuals unnecessary worry. Here we have determined which genetic mutations tend to occur early in IBD-associated bowel cancer development. These mutations could form the basis of a simple diagnostic test for predicting who is at high risk."

Establishing a sequence of genetic events

The team looked at the genetic sequences of cancerous and non-cancerous tissue samples collected from patients with IBD-associated colorectal cancer. By comparing the sequences, the researchers were able to establish a timeline of events leading to the development of malignancy.

Notably, the analysis identified some genetic alterations that tended to occur early in the progression to cancer, such as changes to the 'tumour suppressor' protein known as p53. Changes to p53 that result in the alteration or loss of its function usually occur later in the development of bowel cancers that are not associated with IBD, highlighting some genetic differences between cases that have developed from IBD and those that have not.

Changes in the number of copies of some chromosomes- the structures that carry our genetic information in the form of genes- were also common in the large majority of IBD-associated bowel cancer samples and accumulated early in their evolutionary timeline.

The team hope that spotting these early genetic changes could be used as indicators to identify which patients with IBD are at immediate risk of bowel cancer, prompting close surveillance of the patient and permitting timely interception with the best treatment options. On the other hand, IBD sufferers not at risk of cancer development could be spared unnecessary worry.

Future directions

First author Dr. Annie Baker from Barts Cancer Institute at Queen Mary said: "In this exciting research we studied how IBD-associated bowel develops over time, identifying crucial genetic changes that occur either prior to or at the onset of malignancy. Our findings have provided a strong foundation for future work, which will focus on how we can use this knowledge to improve how doctors assess, monitor and treat IBD in the clinic."

Explore further: Researchers find unique genetic patterns for sub-types of bowel cancer

Related Stories

Researchers find unique genetic patterns for sub-types of bowel cancer

April 5, 2018
A University of Otago, Christchurch, researcher has for the first time identified unique genetic patterns for four different sub-types of colorectal cancer – which respond differently to a variety of cancer treatments.

Don't waste the simple test that might save your life

May 15, 2018
Research reveals many Australians aged 50 and over are putting their lives at risk by not taking part in a simple, painless bowel cancer screening test that is provided free and taken in the privacy of their own homes.

Colorectal cancer—combined analysis enhances risk prediction

February 27, 2018
First-degree relatives affected by colorectal cancer comprise a patient's elevated risk of developing bowel cancer. The same holds true for people who have large numbers of genetic risk markers in their genome. Both factors ...

Personalised medicine approach to improve quality of life for bowel cancer patients

March 19, 2018
Researchers from Queen's University Belfast have demonstrated for the first time how molecular analysis of clinical trial biopsy samples can be used to help clinicians identify the key changes that occur in an individual ...

A new, streamlined approach to diagnosing and treating bowel cancer

April 17, 2018
Researchers at the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide have discovered a faster, more cost-effective way to determine which DNA mutations cause human bowel cancer.

Researchers closer to genetic risk test for bowel cancer

February 4, 2016
University of Melbourne researchers are working to unlock more genetic variants that could predict a person's risk of developing bowel cancer.

Recommended for you

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

Understanding epilepsy in pediatric tumors

September 20, 2018
Pediatric brain tumors are characterized by frequent complications due to intractable epilepsy compared to adult brain tumors. However, the genetic cause of refractory epilepsy in pediatric brain cancer has not been elucidated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.